Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 700,700 shares, a decrease of 6.9% from the August 15th total of 752,900 shares. Approximately 6.9% of the company’s shares are sold short. Based on an average daily trading volume, of 154,100 shares, the short-interest ratio is currently 4.5 days.
Inhibrx Trading Down 1.3 %
NASDAQ INBX opened at $16.99 on Thursday. The firm’s 50 day moving average is $13.87 and its 200-day moving average is $23.42. Inhibrx has a 12-month low of $10.80 and a 12-month high of $18.95.
Inhibrx (NASDAQ:INBX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.60) by $129.08. The business had revenue of $0.10 million during the quarter. As a group, research analysts predict that Inhibrx will post 87.5 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Research Report on INBX
Insider Activity at Inhibrx
In related news, CEO Mark Lappe bought 26,963 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average cost of $15.05 per share, for a total transaction of $405,793.15. Following the acquisition, the chief executive officer now owns 692,511 shares of the company’s stock, valued at approximately $10,422,290.55. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders bought a total of 105,679 shares of company stock worth $1,630,337 in the last quarter. Corporate insiders own 22.20% of the company’s stock.
Institutional Trading of Inhibrx
A number of hedge funds and other institutional investors have recently modified their holdings of INBX. Vestal Point Capital LP acquired a new position in Inhibrx during the fourth quarter valued at approximately $58,140,000. PFM Health Sciences LP raised its stake in shares of Inhibrx by 86.4% during the 4th quarter. PFM Health Sciences LP now owns 537,964 shares of the company’s stock worth $20,443,000 after purchasing an additional 249,347 shares in the last quarter. MMCAP International Inc. SPC acquired a new stake in shares of Inhibrx in the 1st quarter valued at approximately $15,782,000. Charles Schwab Investment Management Inc. grew its stake in shares of Inhibrx by 8.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock valued at $8,735,000 after buying an additional 17,762 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Inhibrx by 8.5% during the first quarter. Swiss National Bank now owns 42,000 shares of the company’s stock worth $1,468,000 after buying an additional 3,300 shares during the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- How Can Investors Benefit From After-Hours Trading
- How Much Can You Make in Stocks in One Month?
- Conference Calls and Individual Investors
- This Is the Top Large-Cap Stock Insiders Are Buying
- Want to Profit on the Downtrend? Downtrends, Explained.
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.